Treatment Strategies for Unruptured Intracranial Aneurysms in the Chinese Population China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA) (ChTUIA)

The goal of this prospective observational cohort study is to learn about treatment strategies for unruptured intracranial aneurysms in the Chinese population. The main questions it aims to answer are:

• To establish a cohort of patients with intracranial unruptured aneurysm and explore the optimal clinical treatment strategy.
• To establish clinical management path for patients with unruptured intracranial aneurysm.

According to the treatment of all patients with unruptured intracranial aneurysm, they were divided into the following groups: 1. Conservative treatment group; 2. Intracranial aneurysm clipping group; 3. Coil embolization or stent-assisted coil embolization group; 4. Flow diversion group.

Study Overview

• Status: Completed
• Conditions: Unruptured Intracranial Aneurysm
• Intervention / Treatment: Other: observation

• Study Type: Observational
• Enrollment (Actual): 31595

Contacts and Locations

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China
      • Capital Medical University Affiliated Beijing Tiantan Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients with unruptured intracranial aneurysm

Description

Inclusion Criteria:

A. age > 18 years. B. at least one intracranial aneurysm needs to be treated by craniotomy, endovascular treatment or combined surgery.

C. patients' consent were obtained.

Exclusion Criteria:

1. Ruptured intracranial aneurysms, accompanied by subarachnoid hemorrhage or cerebral hemorrhage ;
2. Traumatic, infectious and atrial myxoma-associated intracranial aneurysms ;
3. Combined with cerebrovascular malformations;
4. Combined with brain tumors or malignant tumors in other parts ;
5. Combined with systemic connective tissue disease and systemic rheumatic disease ;
6. Due to other diseases, or poor general condition, the expected survival time is not more than 12 months ;
7. During pregnancy and perinatal period.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Intracranial aneurysm clipping group; Patients in Intracranial aneurysm clipping group receive neurosurgical clipping.	Other: observation; observation
Coil embolization or stent-assisted coil embolization group; Patients in coil embolization or stent-assisted coil embolization group receive coil embolization or stent-assisted coil embolization according to individualized condition.	Other: observation; observation
Flow diversion group.; Patients in flow diversion group receive flow diverters.	Other: observation; observation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Outcome	Functional outcomes(modified Rankin Scale,mRS) at 2 years after treatment decision	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
MACCE events	Incidence of major adverse cardiovascular/cerebrovascular events (MACCE events) in patients with atherosclerotic heart disease within 1 year after treatment decision.	1 years
cardiovascular/cerebrovascular events	Incidence of cardiovascular/cerebrovascular events in 2 years after receiving different treatment strategies.	2 years
Cost	Costs associated with unruptured intracranial aneurysms within 2 years after treatment with different strategies.	2 years
Aneurysm-related bleeding events	Incidence of aneurysmal-related bleeding events within 2 years after receiving different treatment strategies.	2 years
Mortality associated with intracranial aneurysms	Mortality associated with intracranial aneurysms within 2 years after treatment with different strategies	2 years
All-cause mortality	All-cause mortality of patients within 2 years after different treatment strategies.	2 years

Collaborators and Investigators

• Sponsor: Beijing Tiantan Hospital
• Collaborators: Peking University First Hospital; The First Affiliated Hospital of Anhui Medical University; Beijing Friendship Hospital; Chinese PLA General Hospital; The Second Hospital of Hebei Medical University; Peking University Third Hospital; First Affiliated Hospital, Sun Yat-Sen University; RenJi Hospital; Huashan Hospital; West China Hospital; Qilu Hospital of Shandong University; First Affiliated Hospital of Fujian Medical University; Shengjing Hospital; First Affiliated Hospital Xi'an Jiaotong University; Xuanwu Hospital, Beijing; Beijing Chao Yang Hospital; Beijing Hospital; The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Zhengzhou University; Qingdao Municipal Hospital; Guizhou Provincial People's Hospital; The First Affiliated Hospital of Guangzhou Medical University; The First Hospital of Jilin University; Fifth Affiliated Hospital of Zhengzhou University; Tianjin Medical University General Hospital; Fujian Medical University Union Hospital; The Affiliated Hospital Of Guizhou Medical University; Shenzhen Second People's Hospital; General Hospital of Ningxia Medical University; Second Affiliated Hospital of Soochow University; Qinghai People's Hospital; The First Affiliated Hospital of Shanxi Medical University; Second Xiangya Hospital of Central South University; First Affiliated Hospital of Xinjiang Medical University; Sichuan Provincial People's Hospital; Second Affiliated Hospital of Nanchang University; First Affiliated Hospital of Chongqing Medical University; Wuhan TongJi Hospital; The Affiliated Hospital of Xuzhou Medical University; First Affiliated Hospital of Harbin Medical University; Anhui Provincial Hospital; Inner Mongolia People's Hospital; The Second Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Xiamen University; The Second Affiliated Hospital of Kunming Medical University; First Affiliated Hospital of Guangxi Medical University; Tibet Autonomous Region People's Hospital; Guangzhou Red Cross Hospital; The General Hospital of Eastern Theater Command; Tangshan Gongren Hospital; Shanxi Provincial People's Hospital; Tianjin Huanhu Hospital; Qilu Hospital of Shandong University (Qingdao); Chongqing General Hospital; Lanzhou University Second Hospital; The Second Affiliated Hospital of Hainan Medical University; Binzhou Medical University; The First Dongguan Affiliated Hospital of Guangdong Medical University; Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China; Xijing hospital of The fourth military medical university; First Affiliated Hospital of Kunming Medical University; The General Hospital of Northern Theater Command; Affiliated hospital of Guilin medical university,China; Changhai Hospital, Naval Medical University; Xunxian People's Hospital; The Second Affiliated Hospital Zhejiang University School of Medcine; Nanfang Hospital, Southern Medical University; Jiangnan University Medical Center; First Affiliated Hospital of China Medical University; National Center for Neurological Disorders (China); Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University; Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; The Southwest Hospital of Army Medical University; The second People's Hospital of Guiyang; Second People's Hospital of Tibet Autonomous Region; School of brain science and brain medicine, Zhejiang University
• Investigators: Study Chair: Wang shuo, M.D., Beijing Tiantan Hospital

Publications and helpful links

General Publications

• Zheng K, Wen Z, Wang K, Mo S, Wu J, Chen X, Zhao B, Liu Q, Wang S. Treatment strategies for unruptured intracranial aneurysms in the Chinese population: China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA). Chin Neurosurg J. 2025 Apr 3;11(1):8. doi: 10.1186/s41016-025-00394-7.

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2021
• Primary Completion (Actual): December 1, 2024
• Study Completion (Actual): December 1, 2024

Study Registration Dates

• First Submitted: April 25, 2023
• First Submitted That Met QC Criteria: April 25, 2023
• First Posted (Actual): May 6, 2023

Study Record Updates

• Last Update Posted (Actual): April 6, 2026
• Last Update Submitted That Met QC Criteria: April 1, 2026
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Intracranial Arterial Diseases; Aneurysm; Intracranial Aneurysm; Investigative Techniques; Methods; Observation
• Other Study ID Numbers: KY2022-226

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No